About Us
ClonalStem makes low passage, clonally isolated cord blood-derived endothelial colony-forming cells commercially accessible—complementing established endothelial models and broadening access to vascular biology research.
Leadership
Translational scientist and biotech entrepreneur with a scientific background spanning small-molecule drug screening to IND-enabling cell and gene therapy, including a successful FDA pre-IND. He also brings expertise in venture creation, commercialization, operations, and investments. Committed to translating breakthrough biology into scalable therapies that improve patient quality of life.
Serial entrepreneur translating breakthrough science into transformative new medicines. Over the last decade, he has founded and advanced multiple biotechnology ventures — securing over $365M in capital to bring several first-in-class, disease-modifying therapies into clinical development.